Factores ambientales en el desarrollo y evolución de la enfermedad inflamatoria intestinal

Meligrana, Noelia E.; Quera, Rodrigo; Figueroa, Carolina; Ibáñez, Patricio; Lubascher, Jaime; Kronberg, Udo; Flores, Lilian; Simian, Daniela

doi:10.4067/s0034-98872019000200212

Cited by 4 publications

(1 citation statement)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…a colitis ulcerosa (CU) es una enfermedad inflamatoria intestinal (EII) que compromete la mucosa del recto y del colon y que se presenta con alternancia de períodos de actividad y remisión 1 . Su patogénesis es multifactorial, e incluye factores genéticos, defectos en la barrera intestinal, trastornos en la regulación de la respuesta inmune, alteraciones en la microbiota intestinal y factores ambientales 1,2 . Su incidencia y prevalencia ha ido aumentando a nivel mundial y en Latinoamérica 3,4 , publicaciones en nuestro país evidencian esta misma tendencia 5,6 .…”

unclassified

Tofacitinib en el tratamiento de la colitis ulcerosa: casos clínicos

Quera

Flores

Núñez³

et al. 2020

Rev. méd. Chile

Self Cite

View full text Add to dashboard Cite

Tofacitinib for the treatment of ulcerative colitis. Report of two cases Biological therapy dramatically changed the management of Ulcerative Colitis (UC). However, a significant number of these patients fail to respond or have secondary loss of response to this strategy. In this clinical situation, the options include intensification of anti-TNF therapy, the use of a second anti-TNF or being switched to another drug class. Among the later, tofacitinib, an oral small molecule directed against the JAK/STAT pathway, is safe and effective in inducing and maintaining remission in patients with moderate-severe UC. We report two patients with UC refractory to conventional treatment and biological therapy, who responded successfully to the use of tofacitinib.

show abstract